SavedAdd your journal

Journals / Adıyaman Üniversitesi Fen Bilimleri Dergisi / 2021 / Cilt: 11 - Sayı: 1

Analysis of Interactions of NHC Type Molecules and NHC-Ag Complexes with VEGFR-2 and DNA: A Molecular Docking Study

Elvan ÜSTÜN
Neslihan ŞAHİN
Pages
113–125
Publication Date
2021-06-30
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this study, the interaction of 1-allyl-3-benzylbenzimidazolium, 1-allyl-3-(naphthylmethyl)benzimidazolium, 1-allyl-3-(anthracen-9-yl-methyl)benzimidazolium,chloro[1-allyl-3-benzylbenzimidazolium-2-ylidene]silver(I), chloro[1-allyl-3-(naphthylmethyl)benzimidazolium-2-ylidene]silver(I), chloro[1-allyl-3-(anthracen-9-yl-methyl)benzimidazolium-2-ylidene]silver(I) with VEGFR-2 and DNA were analyzed by molecular docking methods.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Molecular docking is an important tool in drug research.
📊
Key Findings & Data:One of these receptors is VEGFR-2.
💡
Conclusion & Impact:In this study, the interaction of 1-allyl-3-benzylbenzimidazolium, 1-allyl-3-(naphthylmethyl)benzimidazolium, 1-allyl-3-(anthracen-9-yl-methyl)benzimidazolium,chloro[1-allyl-3-benzylbenzimidazolium-2-ylidene]silver(I), chloro[1-allyl-3-(naphthylmethyl)benzimidazolium-2-ylidene]silver(I), chloro[1-allyl-3-(anthracen-9-yl-methyl)benzimidazolium-2-ylidene]silver(I) with VEGFR-2 and DNA were analyzed by molecular docking methods.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Molecular docking · N-Heterocyclic carbenes · VEGFR-2

Abstract

Molecular docking is an important tool in drug research. Thanks to these calculations, the type and magnitude of interactions of the molecules with target molecules are evaluated. It is also possible to perform more detailed analyzes than known experimental methods in an easy and economical way by using the results obtained with current scientific developments and examine interactions with different target molecules depending on bioactivity type. Cancer researches show that vascular endothelial growth factor is effective in the growth and proliferation of cancer cells. Inhibition of the receptor that regulates the release of this factor may be an efficient method for designing an anticancer agent. One of these receptors is VEGFR-2. This receptor can be used as a target molecule in cancer research. In addition, the interaction of molecules with DNA is important in terms of getting insight for future studies. In this study, the interaction of 1-allyl-3-benzylbenzimidazolium, 1-allyl-3-(naphthylmethyl)benzimidazolium, 1-allyl-3-(anthracen-9-yl-methyl)benzimidazolium,chloro[1-allyl-3-benzylbenzimidazolium-2-ylidene]silver(I), chloro[1-allyl-3-(naphthylmethyl)benzimidazolium-2-ylidene]silver(I), chloro[1-allyl-3-(anthracen-9-yl-methyl)benzimidazolium-2-ylidene]silver(I) with VEGFR-2 and DNA were analyzed by molecular docking methods.

🔖

Cite This Article

ÜSTÜN, E., ŞAHİN, N. (2021). Analysis of Interactions of NHC Type Molecules and NHC-Ag Complexes with VEGFR-2 and DNA: A Molecular Docking Study. Adıyaman Üniversitesi Fen Bilimleri Dergisi, Cilt: 11 - Sayı: 1, 113–125. https://ajindex.com/articles/451022

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Auerbach, W., & Auerbach, R., Angiogenesis inhibition: a review, Pharmacology & therapeutics, 63(3), 265-311, 1994.
  2. Otrock, Z. K., Mahfouz, R. A., Makarem, J. A., & Shamseddine, A. I., Understanding the biology of angiogenesis: review of the most important molecular mechanisms. Blood Cells, Molecules, and Diseases, 39(2), 212-220, 2007.
  3. Weidner, N., Tumor angiogenesis: review of current applications in tumor prognostication. In Seminars in diagnostic pathology, Vol. 10, No. 4, 302, 1993.
  4. Shahi, P. K., & Pineda, I. F., Tumoral angiogenesis: review of the literature, Cancer investigation, 26(1), 104-108, 2008
  5. Ferrara, N., Vascular endothelial growth factor and the regulation of angiogenesis, Recent progress in hormone research, 55, 15, 2000.
  6. Chung, A. S., & Ferrara, N., Developmental and pathological angiogenesis, Annual review of cell and developmental biology, 27, 563-584, 2011.
  7. Matulonis, U. A., Berlin, S., Ivy, P., Tyburski, K., Krasner, C., Zarwan, C., & Lee, H., Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer, Journal of clinical oncology, 27(33), 5601, 2009
  8. Parr, C., Watkins, G., Boulton, M., Cai, J., & Jiang, W. G., Placenta growth factor is over-expressed and has prognostic value in human breast cancer, European Journal of Cancer, 41(18), 2819-2827, 2005.
  9. Strumberg, D., Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment, Drugs Today (Barc), 41(12), 773-784, 2005
  10. Zhang, P. C., Liu, X., Li, M. M., Ma, Y. Y., Sun, H. T., Tian, X. Y.,. & Chen, H. Y., AT-533, a novel Hsp90 inhibitor, inhibits breast cancer growth and HIF-1α/VEGF/VEGFR-2-mediated angiogenesis in vitro and in vivo, Biochemical Pharmacology, 172, 113771, 2020.
  11. Sana, S., Reddy, V. G., Bhandari, S., Reddy, T. S., Tokala, R., Sakla, A. P.,. & Shankaraiah, N., Exploration of carbamide derived pyrimidine-thioindole conjugates as potential VEGFR-2 inhibitors with anti-angiogenesis effect, European Journal of Medicinal Chemistry, 112457, 2020.
  12. Abdel-Mohsen, H. T., Abdullaziz, M. A., Kerdawy, A. M. E., Ragab, F. A., Flanagan, K. J., Mahmoud, A. E.,. & Senge, M. O., Targeting Receptor Tyrosine Kinase VEGFR-2 in Hepatocellular Cancer: Rational Design, Synthesis and Biological Evaluation of 1, 2-Disubstituted Benzimidazoles, Molecules, 25(4), 770, 2020. El‐Adl, K., El‐Helby, A. G. A., Sakr, H., Ayyad, R. R., Mahdy, H. A